Table 3.

Disproportionality analysis of cognitive impairment or dementia associated with the use of individual benzodiazepines from KIDS-KD, 2007–2016^*

		Before matching						After matching on age and sex (1:10)
		ROR	95% CI		Adjusted ROR†	95% CI		ROR	95% CI		Adjusted ROR†	95% CI
			Lower limit	Upper limit		Lower limit	Upper limit		Lower limit	Upper limit		Lower limit	Upper limit
Short-acting benzodiazepines
	Etizolam	1.36	0.42	4.36	1.55	0.48	5.03	1.20	0.33	4.36	1.26	0.28	5.64
	Midazolam	0.49	0.21	1.15	0.44	0.18	1.05	0.46	0.19	1.12	0.36	0.13	1.00
	Tofisopam	1.59	0.22	11.54	1.53	0.20	11.44	0.73	0.09	6.07	0.76	0.08	7.33
	Triazolam	0.77	0.19	3.15	0.73	0.17	3.03	0.86	0.19	3.93	0.77	0.15	4.04
Intermediate-acting benzodiazepines
	Alprazolam	1.13	0.60	2.14	1.23	0.64	2.36	1.24	0.61	2.52	1.72	0.75	3.97
	Bromazepam	3.31	0.46	24.05	3.16	0.42	23.91	2.61	0.23	29.28	1.56	0.12	20.17
	Flunitrazepam	8.75	2.11	36.31	7.32	1.64	32.58	2.64	0.47	14.77	1.38	0.15	12.53
	Lorazepam	1.53	0.88	2.67	1.64	0.93	2.90	1.92	1.03	3.57	1.67	0.81	3.43
Long-acting benzodiazepines
	Clonazepam	0.81	0.32	2.03	0.71	0.28	1.79	0.61	0.23	1.62	0.72	0.24	2.16
	Diazepam	0.79	0.32	1.98	0.80	0.32	2.02	0.88	0.33	2.38	1.05	0.32	3.43

^*analysis based on logistic on analysis, reference group: other benzodiazepines. This table displays only benzodiazepines referenced in over 100 reports,

^†adjusted according to age group, sex, year of reporting, and polypharmacy.

KIDS-KD: Korea Institute of Drug Safety & Risk Management-Korea adverse event reporting system database, ROR: reporting odds ratio, 95% CI: 95% confidence interval